Risk Stratification in Hypertrophic Cardiomyopathy.

Area of Science:

• Cardiology
• Genetics
• Molecular Biology

Background:

• Hypertrophic cardiomyopathy (HCM) is an inherited heart muscle disease characterized by left ventricular hypertrophy.
• It is primarily caused by mutations in genes encoding sarcomeric proteins.
• The main concern is the risk of fatal ventricular arrhythmias and sudden cardiac death (SCD).

Purpose of the Study:

• To review the current strategies for identifying patients at risk of SCD in HCM.
• To discuss the role and challenges of implantable cardioverter-defibrillator (ICD) therapy for primary and secondary prevention of SCD.
• To highlight the need for improved risk stratification models in HCM.

Main Methods:

• Review of existing literature on HCM, SCD risk factors, and ICD therapy.
• Analysis of the limitations of current risk stratification methods.
• Discussion of emerging risk models and their validation needs.

Main Results:

• Aborted SCD and malignant ventricular arrhythmias are strong indicators for ICD implantation (secondary prevention).
• Primary prevention of SCD with ICDs is challenging due to the heterogeneous nature of HCM and variable risk factors.
• A new European Society of Cardiology risk model shows potential but requires further validation.

Conclusions:

• ICD therapy is effective in preventing SCD in HCM patients with a history of aborted SCD or malignant arrhythmias.
• Accurate risk stratification is essential to select appropriate candidates for primary prevention ICD implantation, balancing benefits against potential complications.
• Continued research is needed to refine risk prediction models for HCM patients to optimize ICD use.